局部晚期非小细胞肺癌同步放化疗后度伐利尤单抗治疗出现症状性放射性肺炎的预测因素
该回顾性研究纳入2018年7月至2019年12月间完成同步放化疗并接受至少1周期度伐利尤单抗巩固治疗的局部晚期非小细胞肺癌患者,分析症状性放射性肺炎的发生率及预测因素。中位度伐利尤单抗永久停药时间为9.7个月,症状性放射性肺炎3、6、12个月累积发生率分别为30%、40%和44%。多因素分析显示肺纤维化评分(p<0.001,HR 7.83,95%CI 3.38-18.13)和肺V40(p=0.034,HR 3.17,95%CI 1.09-9.19)是症状性放射性肺炎的显著预测因素。
要点
- 症状性放射性肺炎3、6、12个月累积发生率分别为30%、40%、44%。
- 肺纤维化评分是症状性放射性肺炎的显著预测因素(p<0.001,HR 7.83,95%CI 3.38-18.13)。
- 肺V40是症状性放射性肺炎的显著预测因素(p=0.034,HR 3.17,95%CI 1.09-9.19)。
核心结论
- 肺纤维化评分和肺V40是局部晚期非小细胞肺癌患者同步放化疗后度伐利尤单抗治疗出现症状性放射性肺炎的显著预测因素。
研究设计与样本
- 回顾性分析2018年7月至2019年12月间病理诊断为非小细胞肺癌并启动同步放化疗后度伐利尤单抗治疗的患者,纳入完成计划放化疗疗程且接受至少1周期度伐利尤单抗者,共67例计划同步放化疗,63例完成全部同步放化疗疗程,其中56例接受度伐利尤单抗巩固治疗。
主要发现
- 度伐利尤单抗永久停药的中位时间为9.7个月。
- 症状性放射性肺炎的累积发生比例在3、6、12个月分别为30%、40%和44%。
- 多因素分析中,肺纤维化评分对症状性放射性肺炎的p<0.001,HR为7.83,95%CI为3.38-18.13。
- 多因素分析中,肺V40对症状性放射性肺炎的p=0.034,HR为3.17,95%CI为1.09-9.19。
临床怎么用
- 作者认为,对于存在亚临床肺纤维化的患者,应谨慎使用度伐利尤单抗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard of care for unresectable locally-advanced non-small cell carcinoma (LA-NSCLC). However, a major concern about administration of durvalumab after CCRT is whether the incidence of symptomatic radiation pneumonitis (RP) may increase or not. In the present analysis, we report the initial results of CCRT followed by durvalumab in patients with LA-NSCLC in a real-world setting with focus on predicting factors for symptomatic RP. METHODS: Patients who were pathologically diagnosed as NSCLC and initiated treatment with CCRT followed by durvalumab between July 2018 to December 2019 were eligible for this study. Patients were included if they completed the planned CRT course and administered at least one course of durvalumab. We retrospectively investigated the preliminary survival outcome and incidence and predicting factors for symptomatic RP. RESULTS: Of the 67 patients who planned CCRT, 63 patients completed the entire CCRT course. Of these, 56 patients proceeded to consolidation with durvalumab. The median time to eternal discontinuation of durvalumab was 9.7 months. The cumulative proportion of the patients who exhibited symptomatic RP was 30, 40 and 44% at 3, 6 and 12 months, respectively. In multivariate analyses, pulmonary fibrosis score and lung V40 were significant predictive factors for symptomatic RP (p < 0.001, HR: 7.83, 95% CI: 3.38-18.13, and p = 0.034, HR: 3.17, 95% CI: 1.09-9.19, respectively). CONCLUSIONS: Pulmonary fibrosis sore and lung V40 were significant predictive factors for symptomatic RP. We should be cautious about the administration of durvalumab for patients having subclinical pulmonary fibrosis. To our best knowledge, this is one of the first report showing the predictive value of high dose volumes to the lung in patients with LA-NSCLC who received CCRT followed by durvalumab.
引用
- Mayahara H, Uehara K, Harada A, et al. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Radiat Oncol. 2022. PMID: 35033139. doi:10.1186/s13014-021-01979-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。